These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

570 related items for PubMed ID: 14504182

  • 1. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
    Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, Diaz R, Commerford PJ, Valentin V, Yusuf S, Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators.
    Circulation; 2003 Oct 07; 108(14):1682-7. PubMed ID: 14504182
    [Abstract] [Full Text] [Related]

  • 2. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
    Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, Yusuf S, Clopidogrel in Unstable angina to prevent Recurrent ischemic Events Trial.
    Circulation; 2004 Sep 07; 110(10):1202-8. PubMed ID: 15313956
    [Abstract] [Full Text] [Related]

  • 3. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease.
    Mehta SR, Yusuf S, Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators.
    Eur Heart J; 2000 Dec 07; 21(24):2033-41. PubMed ID: 11102254
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.
    Vavuranakis M, Latsios G, Aggelis D, Bosinakou I, Karambelas I, Tousoulis D, Toutouzas K, Stefanadis C.
    Clin Ther; 2006 Jun 07; 28(6):860-71. PubMed ID: 16860169
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
    Chin CT, Roe MT, Fox KA, Prabhakaran D, Marshall DA, Petitjean H, Lokhnygina Y, Brown E, Armstrong PW, White HD, Ohman EM, TRILOGY ACS Steering Committee.
    Am Heart J; 2010 Jul 07; 160(1):16-22.e1. PubMed ID: 20598967
    [Abstract] [Full Text] [Related]

  • 9. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
    APPRAISE Steering Committee and InvestigatorsDuke Clinical Research Institute, Duke University Medical Center, DUMC Box 3850, Durham, NC 27715, USA. john.h.alexander@duke.edu, Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L.
    Circulation; 2009 Jun 09; 119(22):2877-85. PubMed ID: 19470889
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
    Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E, TRITON-TIMI 38 Investigators.
    Am Heart J; 2006 Oct 09; 152(4):627-35. PubMed ID: 16996826
    [Abstract] [Full Text] [Related]

  • 12. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?
    Gerschutz GP, Bhatt DL, Clopidogrel in Unstable Angina to Prevent Recurrent Events study.
    Am Heart J; 2003 Apr 09; 145(4):595-601. PubMed ID: 12679754
    [Abstract] [Full Text] [Related]

  • 13. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire Int; 2009 Oct 09; 18(103):193-5. PubMed ID: 19877380
    [Abstract] [Full Text] [Related]

  • 14. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
    Antman EM, Wiviott SD, Murphy SA, Voitk J, Hasin Y, Widimsky P, Chandna H, Macias W, McCabe CH, Braunwald E.
    J Am Coll Cardiol; 2008 May 27; 51(21):2028-33. PubMed ID: 18498956
    [Abstract] [Full Text] [Related]

  • 15. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.
    Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF, DISPERSE-2 Investigators.
    J Am Coll Cardiol; 2007 Nov 06; 50(19):1844-51. PubMed ID: 17980250
    [Abstract] [Full Text] [Related]

  • 16. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.
    Morrow DA, Wiviott SD, White HD, Nicolau JC, Bramucci E, Murphy SA, Bonaca MP, Ruff CT, Scirica BM, McCabe CH, Antman EM, Braunwald E.
    Circulation; 2009 Jun 02; 119(21):2758-64. PubMed ID: 19451347
    [Abstract] [Full Text] [Related]

  • 17. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
    Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Fabry-Ribaudo L, Hu T, Topol EJ, Fox KA, CHARISMA Investigators.
    J Am Coll Cardiol; 2007 May 15; 49(19):1982-8. PubMed ID: 17498584
    [Abstract] [Full Text] [Related]

  • 18. Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes.
    Testa L, Zoccai GB, Porto I, Trotta G, Agostoni P, Andreotti F, Crea F.
    Am J Cardiol; 2007 Jun 15; 99(12):1637-42. PubMed ID: 17560866
    [Abstract] [Full Text] [Related]

  • 19. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.
    Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo DJ, Sabatè M, Hamon M, Repetto A, Colangelo S, Brugaletta S, Parrinello G, Percoco G, Ferrari R, Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators.
    Circulation; 2009 Jun 30; 119(25):3215-22. PubMed ID: 19528337
    [Abstract] [Full Text] [Related]

  • 20. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z, Kala P.
    Clin Ther; 2008 Jun 30; 30 Pt 2():2191-202. PubMed ID: 19281914
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.